共 101 条
[1]
Hossain ME(2020)A framework to understand the progression of cardiovascular disease for type 2 diabetes mellitus patients using a network approach Int J Environ Res Public Health 17 596-742
[2]
Uddin S(2016)Evaluating the cardiovascular safety of new medications for type 2 diabetes: time to reassess? Diabetes Care 39 738-1287
[3]
Khan A(2013)The cardiovascular safety of diabetes drugs–insights from the rosiglitazone experience N Engl J Med 369 1285-2135
[4]
Moni MA(2009)Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial Lancet 373 2125-1289
[5]
Smith RJ(2005)Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial Lancet 366 1279-1270
[6]
Goldfine AB(2015)Number needed to harm in the post-marketing safety evaluation: results for rosiglitazone and pioglitazone Pharmacoepidemiol Drug Saf 24 1259-130
[7]
Hiatt WR(2019)Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial Lancet 394 121-49
[8]
Hiatt WR(2018)Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide Diabetes Obes Metab 20 42-1239
[9]
Kaul S(2017)Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes N Engl J Med 377 1228-9
[10]
Smith RJ(2017)Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) Am Heart J 187 1-322